Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Asia "XANAP"


Phase N/A Results N/A

Eligibility Criteria

Inclusion Criteria

- Female and male patients ≥ 18 years of age with a diagnosis of non-valvular atrial fibrillation who start treatment with rivaroxaban to prevent stroke or non-CNS (Central Nervous System) systemic embolism, and who consent to participate in the study.